Risk factors for renal replacement therapy in the Early Treatment Diabetic Retinopathy Study (ETDRS), Early Treatment Diabetic Retinopathy Study Report No. 26

Kidney International

Volumn 66, Issue 3, 2004, Pages 1173-1179

  Cusick, Michael ^b   Chew, Emily Y ^a   Hoogwerf, Byron ^b   Agrón, Elvira ^b   Wu, LieLing ^b   Lindley, Anna ^b   Ferris III, Frederick L ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NONE

Author keywords

Diabetic nephropathy; Renal replacement therapy

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; ANTIHYPERTENSIVE AGENT; CHOLESTEROL; CREATININE; DIURETIC AGENT; HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT; TRIACYLGLYCEROL;

ADULT; AGE; ALBUMIN BLOOD LEVEL; ANEMIA; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL EXAMINATION; CLINICAL STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEMOGRAPHY; DIABETIC RETINOPATHY; DIALYSIS; DISEASE DURATION; FEMALE; HAZARD ASSESSMENT; HEMOGLOBIN DETERMINATION; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; KAPLAN MEIER METHOD; KIDNEY TRANSPLANTATION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEINURIA; REGRESSION ANALYSIS; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 4344645765     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.00869.x     Document Type: Article

References (39)

1. U.S. RENAL DATA SYSTEM, USRDS 2002 ANNUAL DATA REPORT: Atlas of End-Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2002
2. XUE JL, MA JZ, LOUIS TA, COLLINS AJ: Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol 12:2753-2758, 2001
3. ANDERSEN AR, CHRISTENSEN JS, ANDERSEN JK, et al: Diabetic nephropathy in type 1 (insulin-dependent) diabetes: An epidemiologic study. Diabetologia 25:496-501, 1983
4. IBRAHIM HAA, VORA JP: Diabetic nephropathy. Baillière's Clin Endocrinol Metab 13:239-264, 1999
5. HASSLACHER C, RITZ E, WAHL P, MICHAEL C: Similar risks of nephropathy in patients with type I or type II diabetes mellitus. Nephropath Dial Transplant 4:859-863, 1989
6. SKYLER JS: Microvascular complications. Endocrinol Metab Clin North Am 30:833-856, 2001
7. COLHOUN HM, LEE ET, BENNETT PH, et al: Risk factors for renal failure: The WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 44:S46-S53, 2001
8. KRAMER HJ, NGUYEN QD, CURHAN G, Hsu C: Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 289:3273-3277, 2003
9. DEFRONZO RA: Diabetic nephropathy, in Ellenberg and Rifkin's Diabetes Mellitus: Theory and Practice, 5th ed, edited by Porte D, Sherwin RS, Ellenberg, McGraw-Hill, 1998, pp 971-1008
10. PARVING HH, GALL MA, SKOTT P, et al: Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients. Kidney Int 4:758-762, 1992
11. EARLY TREATMENT DIABETIC RETINOPATHY STUDY RESEARCH GROUP: Early Treatment Diabetic Retinopathy Study Design and Baseline Patient Characteristics. Early Treatment Diabetic Retinopathy Study Report Number 7. Ophthalmology 98:741-756, 1991
12. EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001
13. CHOBANIAN AV, BAKRIS GL, BLACK HR, et al: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 289:2560-2571, 2003
14. MATHIESEN ER, RONN B, STORM B, et al: The natural course of microalbuminuria in insulin-dependent diabetes: A 10-year prospective study. Diabetic Med 12:482-487, 1995
15. MESSENT JW, ELLIOT TG, HILL RG, et al: Prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus: A twenty-three-year follow-up study. Kidney Int 41:836-839, 1992
16. ROSSING P, HOMMEL E, SMIDT UM PARVING HH: Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients. Diabetes 42:715-719, 1993
17. VIBERTI GC, HILL RD, JARRETT RJ, at el: Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1:1430-1432, 1982
18. MOGENSEN CE: Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 310:356-360, 1984
19. JOHN L, RAO PS, KANAGASABAPATHY AS: Rate of progression of albuminuria in type II diabetes. Five-year prospective study from south India. Diabetes Care 17:888-890, 1994
20. CRUICKSHANKS KJ, RITTER LL, KLEIN R, MOSS SE: The association of microalbuminuria with diabetic retinopathy. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Ophthalmology 100:862-867, 1993
21. YOKOYAMA H, TOMONAGA O, HIRAYAMA M, et al: Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients. Diabetologia 40:405-411, 1997
22. KEANE WF: Lipids and progressive renal disease: The cardio-renal link. Am J Kidney Dis 34:xliii-xlvi, 1999
23. YANG WQ, SONG NG, YING SS, et al: Serum lipid concentrations correlate with the progression of chronic renal failure. Clin Lab Sci 12:104-108, 1999
24. CHANDRA M, CLEMONS GK, MCVICAR MI: Relation of serum erythropoietin levels to renal excretory function: Evidence for lowered set point for erythropoietin production in chronic renal failure. J Pediatr 113:1015-1021, 1988
25. RATKE HW, CLAUSSNER A, ERBES PM, et al: Serum erythropoietin concentration in chronic renal failure: Relationship to degree of anemia and excretory renal function. Blood 54:877-884, 1979
26. DAVIS MD, FISHER MR, GANGNON RE, et al: Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Invest Ophthalmol Vis Sci 39:233-252, 1998
27. BOSMAN DR, WINKLER AS, MARSDEN JT, et al: Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care 24:495-499, 2001
28. BREYER JA, BAIN RP, EVANS JK, et al: Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. Kidney Int 50:1651-1658, 1996
29. KANNEL WB, WOLF PA, CASTELLI WP, D'Agostino RB: Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 258:1183-1186, 1987
30. KLEIN RL, HUNTER SJ, JENKINS AJ, et al, AND THE DCCT/EDIC STUDY GROUP: Fibrinogen is a marker for nephropathy and peripheral vascular disease in type 1 diabetes. Diabetes Care 26:1439-1448, 2003
31. STEHOUWER CDA, GALL M-A, TWISK JWR, et al: Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes. Diabetes 51:1157-1165, 2002
32. REMUZZI G, BERTANI T: Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int 38:384-394, 1990
33. PRIOR MJ, PROUT T, MILLER D, et al, THE ETDRS RESEARCH GROUP: C-peptide and the classification of diabetes mellitus patients in the Early Treatment Diabetic Retinopathy Study. Report Number 6. Ann Epidemiol 3:9-17, 1993
34. THE DIABETES CONTROL AND COMPLICATIONS TRIAL RESEARCH GROUP: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
35. UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
36. NIELSON S, SCHMITZ O, MOLLER N, et al: Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin dependent) diabaetic patients with microalbminura. Diabetologia 36:1079-1086, 1993
37. LAM KS, CHENG IKP, JANUS ED, PANG RWC: Cholesterol-lowering therapy may retard the progression of diabetic nephropoathy. Diabetologia 38:604-609, 1995
38. CHAN PCK, ROBINSON JD, YANG WC, et al: Lovastatin in glomerulonephritis patients with hyperlipidemia and heavy proteinuria. Nephrol Dial Transplant 7:93-99, 1992
39. SASAK T, KURATA H, NOMURA K, et al: Amelioration of proteinuria with pravastatin in hypercholesterolemic patients with diabetes mellitus. Jpn J Med 29:156-163, 1990